Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-jRCT2080224041
JPRN-jRCT2080224041
Completed
Phase 2

A phase II randomized double blind placebo-controlled parallel-group multicenter study of KRP-N118 in patients with Nocturia due to nocturnal polyuria

Kyorin Pharmaceutical Co.,LTD0 sites880 target enrollmentSeptember 6, 2018
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsocturia due to nocturnal polyuria.

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
octuria due to nocturnal polyuria.
Sponsor
Kyorin Pharmaceutical Co.,LTD
Enrollment
880
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 6, 2018
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •2 or more nocturnal voids or less 5
  • •Nocturnal polyuria

Exclusion Criteria

  • •Complication or a history of cardiac failure
  • •Hyponatremia
  • •Uncontrolled diabetes mellitus
  • •Uncontrolled hypertension
  • •Severe benign prostate hyperplasia (BPH)
  • •Central or renal diabetes insipidus

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
A Phase II randomized double-blind placebo-controlled Study of KC706 in patients with rheumatoid arthritis inadequately controlled with a stable dose of methotrexateActive rheumatoid arthritis (RA), patients taking stable doses of methotrexateMedDRA version: 8.1Level: LLTClassification code 10039073Term: Rheumatoid arthritis
EUCTR2006-002645-37-HUKémia, Inc.150
Recruiting
Not Applicable
A treatment for brain damage in successfully resuscitated cardiac arrest patientsDiseases of the circulatory system
KCT0007235GNT Pharma150
Recruiting
Phase 2
A phase 2 randomized double-blind placebo-controlled study to evaluate safety of BLD-2660 and its activity against COVID-19 virus in hospitalized subjects recently diagnosed with COVID-19 in comparison to standard of care treatment
RBR-2kjm6yBlade Therapeutics Inc
Completed
Not Applicable
The effect of vitamin supplementation, genotype and homocysteine on migraine frequency and severity in females diagnosed with migraine with aura.Migraine with auraAlternative and Complementary Medicine - Other alternative and complementary medicineNeurological - Other neurological disorders
ACTRN12609000275268Griffith University250
Active, not recruiting
Phase 1
A randomised phase II double blind placebo controlled trial of Whole Brain Radiotherapy (WBRT) and Tarceva (OSI-774, erlotinib) in patients with advanced non-small cell lung cancer (NSCLC) with multiple brain metastases - TACTIC
EUCTR2006-000113-38-GBniversity College London144